Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

AIMday in Healthy Ageing - registration for academics now open

General

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Healthy Ageing.

Networking events, like AIMdays, are one of the ways in which we bring together innovative companies and world-leading academics.

The University of Oxford, together with the UK SPINE Knowledge Exchange, will be hosting an AIMday in Healthy Ageing on Wednesday 9 October 2019 at Blavatnik School of Government. This event will bring together industry with academia to discuss the healthcare challenges associated with ageing. The UK Spine initiative aims to accelerate innovations in ageing and the AIMday will draw on expertise from all the UK Spine’s partners: the University of Oxford, the University of Dundee, the University of Birmingham, the Medicines Discovery Catapult and the Francis Crick Institute.

FREE registration for academics is now open and closes on Friday 27 September (advance registration is essential).

A range of companies including Five Alarm Bio, Isansys, Kemuri, Shift Bioscience (& more) are registered to attend the event and it will be a fantastic opportunity for researchers looking to network with industry and discuss relevant questions.

To see the questions posed by these companies, please visit aimday.se/healthy-ageing-oxford-2019/questions-listing.

Register here: aimday.se/healthy-ageing-oxford-2019/registration-for-researchers

Similar stories

Singula Bio, a new Oxford spin-out company - Cancer need not be fatal

General Innovation Research

Singula Bio, a bold new seed-stage biotechnology company spun out of Oxford University, has been launched with the intention of helping show that cancer need not be fatal. Led by three Oxford cancer specialists, the firm is aims to become a world leader in therapies to use against difficult-to-treat solid malignancies such as ovarian cancer - using the body’s own immune system to fight previously fatal cancers.

Major rise in public support for COVID vaccine – Oxford study

Coronavirus COVID-19 General Research

More than three quarters of people in the UK now say they are ’very likely’ to have the vaccine – up from 50% among the same group of survey respondents five months ago –according to a two-wave Oxford University survey published today.

Three ways virtual reality could transform mental health treatment

General Research

Coronavirus vaccination linked to substantial reduction in hospitalisation, real-world data suggests

Coronavirus COVID-19 General Research

The first study to describe the effects in real-world communities of the Oxford coronavirus vaccine has been reported in a pre-print publication today, showing a clear reduction in the risk of hospitalisation from COVID-19 amongst those who have received the vaccine.

World’s largest clinical trial for COVID-19 treatments expands internationally

Clinical Trials Coronavirus COVID-19 General

The Randomised Evaluation of COVID-19 Therapy (RECOVERY) Trial, the world’s largest clinical trial for COVID-19 treatments, has now expanded internationally with Indonesia and Nepal among the first countries to join. The first patients have been recruited to RECOVERY International.

Reprogramming tumour cells using an antimalarial drug

General Research

Results from the ATOM clinical trial at the University of Oxford have shown that the anti-malarial drug Atovaquone can reduce very low oxygen tumour environments. This has the potential to make cancers behave less aggressively and to improve the impact of everyday cancer treatments.